IceCure Medical Ltd (ICCM) Research

Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.

Market snapshot

Symbol
ICCM
Price
$5.40
Day change
-15.63%
Market cap
$12.2M
P/E ratio
-0.84x
52-week range
2.12-42
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months
Analyst price target
$1.00

Recent news

  • IceCure Stock Surges After 70% ProSense Install Increase

    IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.

Peer companies

  • Baird Medical Investment Holdings Limited (BDMD)
  • Cytosorbents Corporation (CTSO)
  • electroCore, Inc. (ECOR)
  • Spectral AI, Inc. (MDAI)
  • Medicus Pharma Ltd. Common Stock (MDCX)
  • PetMed Express, Inc. (PETS)
  • Sensus Healthcare, Inc. (SRTS)
  • TELA Bio, Inc. (TELA)

Recent insider activity

  • Muchnik Naum — trade (0 shares) on 2026-04-12
  • Tsimerman Ronen — trade (0 shares) on 2026-05-17
  • Peleg Meir — trade (0 shares) on 2026-05-17
  • Malca Yonatan — trade (0 shares) on 2026-03-18
  • Huang Yang — trade (0 shares) on 2026-03-18

Open IceCure Medical Ltd (ICCM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.